New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress

Interim Data From Phase 2 Trial Provides Further Insight Into IMLYGIC® (Talimogene Laherparepvec) as a Potential Combination Partner With a Checkpoint Inhibitor for Patients With Advanced Melanoma Retrospective Analyses of Key Studies Evaluating Vectibix® (Panitumumab) Combination Regimen in First- and Second-Line Metastatic Colorectal Cancer Evaluate Impact of Tumor Site of Origin on Treatment Efficacy

Amgen - Investors - RSS Content